Recombinant Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [ERK12T202Y204-A11] to ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187)
- Suitable for: WB, Flow Cyt
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] -
Description
Rabbit monoclonal [ERK12T202Y204-A11] to ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) -
Host species
Rabbit -
Tested applications
Suitable for: WB, Flow Cytmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human ERK1 (phospho T202 + Y204). The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements. Uniprot P27361/ P28482
Database link: P27361 -
Positive control
- WB: Ramos (treated with PMA or TPA) cell extract; NIH/3T3 (treated with TPA) cell extract. Flow cyt: L929 cells; Jurkat cells (treated with PMA).
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituents: 49.88% PBS, 0.1% BSA, 50% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A/G purified -
Clonality
Monoclonal -
Clone number
ERK12T202Y204-A11 -
Isotype
IgG -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab278538 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 0.05 - 0.1 µg/ml. Predicted molecular weight: 41 kDa.
|
|
Flow Cyt |
Use a concentration of 0.001 - 1 µg/ml.
|
Notes |
---|
WB
Use a concentration of 0.05 - 0.1 µg/ml. Predicted molecular weight: 41 kDa. |
Flow Cyt
Use a concentration of 0.001 - 1 µg/ml. |
Target
-
Cellular localization
ERK2: Nucleus. -
Database links
- Entrez Gene: 5594 Human
- Entrez Gene: 5595 Human
- Entrez Gene: 26413 Mouse
- Entrez Gene: 26417 Mouse
- Omim: 176948 Human
- Omim: 601795 Human
- SwissProt: P27361 Human
- SwissProt: P28482 Human
see all
Images
-
Flow Cytometry - Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538)ab278538 recognizes basal phosphorylation levels in mouse cells. Flow cytometric analysis of L929 cells secondary antibody only (blue) or 0.1 µg/mL of isotype control (orange) or of ab278538.
-
Western blot - Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538)All lanes : Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538) at 0.05 µg/ml
Lane 1 : Ramos (treated with U0126) cell extract
Lane 2 : Ramos (treated with TPA) cell extract
Predicted band size: 41 kDaWestern blot analysis of Ramos cells treated with U0126 or treated with TPA using 0.05 μg/mL of ab278538.
-
Flow Cytometry - Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538)
Flow cytometric analysis of Jurkat cells, secondary antibody only negative control (blue), or treated with U0126 (red) or with PMA (green) using ab278538.
-
Western blot - Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538)All lanes : Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538) at 0.1 µg/ml
Lane 1 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen)(treated with TPA) cell extract .
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) (treated with U0126) cell extract.
Predicted band size: 41 kDa -
Western blot - Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538)All lanes : Anti-ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187) antibody [ERK12T202Y204-A11] (ab278538) at 0.1 µg/ml
Lane 1 : Ramos cell extract untreated
Lane 2 : Ramos cell extract treated with PMA
Lane 3 : Ramos cell extract treated with U0126
Lane 4 : Ramos cell extract treated with U0126 followed by treatment with PMA
Predicted band size: 41 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (7)
ab278538 has been referenced in 7 publications.
- Li J et al. METTL3 Facilitates Tumor Progression by COL12A1/MAPK Signaling Pathway in Esophageal Squamous Cell Carcinoma. J Cancer 13:1972-1984 (2022). PubMed: 35399719
- Sun T et al. Network Pharmacology-Based Strategy Combined with Molecular Docking and in vitro Validation Study to Explore the Underlying Mechanism of Huo Luo Xiao Ling Dan in Treating Atherosclerosis. Drug Des Devel Ther 16:1621-1645 (2022). PubMed: 35669282
- Tian J et al. MIR503HG impeded ovarian cancer progression by interacting with SPI1 and preventing TMEFF1 transcription. Aging (Albany NY) 14:5390-5405 (2022). PubMed: 35771155
- Ma L et al. Investigation of Molecular Mechanism of Banxia Xiexin Decoction in Colon Cancer via Network Pharmacology and In Vivo Studies. Evid Based Complement Alternat Med 2022:4961407 (2022). PubMed: 35815259
- Lu Y et al. Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis In Vitro and In Vivo. Front Immunol 12:649591 (2021). PubMed: 33995368
- Niu L et al. ARHGEF19 promotes the growth of breast cancer in vitro and in vivo by the MAPK pathway. Physiol Int N/A:N/A (2021). PubMed: 34813497
- Wan W et al. MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer's disease. Bioengineered 12:12678-12690 (2021). PubMed: 34818971